Serum alpha-fetoprotein is the standard clinical biomarker for hepatocellular carcinoma. However, a new study from experts at the Cleveland Clinic shows that other emerging biomarkers, such as ...

α-Fetoprotein (AFP) is a tumour-associated antigen in hepatocellular carcinoma (HCC) and is a target for immunotherapy. However, there is little information on the pattern of CD4 (Th1) and CD8 ...

Hepatitis B virus-induced hepatocellular carcinoma (HCC) remains a major global health burden, and new therapeutic and ...

The C-reactive protein and alpha-fetoprotein in immunotherapy score identified patients with favorable hepatocellular carcinoma disease control and survival, according to a study presented at the ...

If the HCC prevalence rates were more like those seen in most liver clinics, ~5%, the positive predictive value (PPV) of an AFP of 20 ng/mL would be only 41.5%, and even at a cutoff of 400 ng/mL ...

Among patients with screen-detected HCC, nearly half were identified through imaging studies alone (44.6%) or by both imaging and AFP tests (44.7%). The remaining 10.6% had HCC identified solely ...

FUJIFILM Healthcare Americas Corporation, a leading provider of diagnostic and enterprise imaging solutions, announced today ...

Early detection of hepatocellular carcinoma (HCC) is crucial for improving survival in patients with chronic hepatitis. The GALAD algorithm combines gender (biological sex), age, α-fetoprotein ...

Hepatocellular carcinoma is a cancer that starts in your liver. ... Unborn babies have high levels of AFP, but it decreases in most people right after birth.

Early detection of hepatocellular carcinoma (HCC) ... The GALAD algorithm combines gender (biological sex), age, α-fetoprotein (AFP), Lens culinaris agglutinin-reactive fraction of AFP ...

REACH-2 was a randomized, double-blind, placebo-controlled trial that enrolled 292 patients with hepatocellular carcinoma (HCC) who were intolerant to, or had disease progression while on or ...